Publications by authors named "A J Bergquist"
Determining the time to cholangiocarcinoma in pediatric-onset PSC-IBD.
J Pediatr Gastroenterol Nutr
December 2024
Primary sclerosing cholangitis (PSC) is a risk factor for cholangiocarcinoma. When a child is diagnosed with both PSC and inflammatory bowel disease (IBD), evidence-based information on counseling families and risk management of developing cholangiocarcinoma is limited. In this case series (PubMed/collaborators), we included patients with PSC-IBD who developed cholangiocarcinoma and contacted authors to determine an event curve specifying the time between the second diagnosis (IBD or PSC) and a diagnosis of cholangiocarcinoma.
View Article and Find Full Text PDFBackground And Aims: Individuals with primary sclerosing cholangitis (PSC) have expressed a need for more dietary information. The aim of this study was to evaluate the dietary intake of individuals with PSC and compare it with Nordic nutrition recommendations 2023 (NNR2023).
Methods: A cross-sectional assessment of dietary intake was performed using a food-frequency questionnaire among 120 individuals with PSC from five regions across Sweden.
It has proven difficult to establish robust evidence for significant clinical benefits of medical treatment in primary sclerosing cholangitis (PSC). For ursodeoxycholic acid, clinical practice guidelines only offer vague recommendations, leading to a situation of variable prescription rates depending on local reimbursement policies and physician preference. The difficulty in drug development in PSC is partly related to a poor understanding of critical disease processes with failure to identify relevant mechanisms of action of putative drugs.
View Article and Find Full Text PDFAim: Sweden has historically provided a fruitful arena for research in clinical medicine. We here share 40 years of experience of collaboration in the Swedish hepatology research group (SWEHEP) (https://www.swehep.
View Article and Find Full Text PDFArticle Synopsis
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is becoming more common and is linked to serious health issues like liver cancer and cardiovascular disease.
- A study evaluated the risk of developing cholangiocarcinoma (CCA) in MASLD patients compared to a matched control group, using data from the Swedish National Patient Register over a span of 33 years.
- The results showed that only 0.1% of MASLD patients developed CCA, which is similar to the 0.3% occurrence in the general population, suggesting that there's no need for increased monitoring for CCA in MASLD patients.